Pharmacist role in transforming Alzheimer’s care: Anti-amyloid therapy experience at Vanderbilt University Medical Center

Clicks: 19
ID: 333845
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #121 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose Anti-amyloid infusion therapies are a new and complex treatment option for patients with Alzheimer’s disease. Use of lecanemab or donanemab requires specific diagnostic criteria and frequent ongoing monitoring that requires in-depth coordination of care. We describe how neurology clinical pharmacists were an integral part of adoption of anti-amyloid therapy at our institution. With implementation of this service by pharmacists, we describe the impact on patient outcomes for those receiving anti-amyloid infusions and several aspects of impact on the health system as a whole that pharmacists should anticipate with these complex infusions. Summary Neurology clinical pharmacists dedicated to infusions therapies are responsible for many aspects of use of anti-amyloid therapies, including order entry, patient counseling, Centers for Medicare and Medicaid Services (CMS) registry submission, infusion scheduling, and coordination of magnetic resonance imaging. At our institution, the first year of anti-amyloid infusions included 58 patients starting infusions. Safety and adverse effects, including amyloid-related imaging abnormalities, were similar to those previously reported in the primary literature. The majority of patients utilized Medicare as their primary coverage for infusions, and we describe successful navigation of the unique CMS registry requirement for billing. Conclusion Adoption of anti-amyloid therapies by a health system requires unique aspects of coordination not previously encountered. Clinical pharmacists are positioned to successfully coordinate care for patients receiving anti-amyloid infusions.
Reference Key
openalex_W7223470739 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rachel Renwick, Cory Rossmann, Shannon Patterson, Jared L Gabbert
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag359
URL
https://doi.org/10.1093/ajhp/zxag359
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.